Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Keytruda (pembrolizumab by Year
Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide sales ($M) ($M)
Merck Keytruda (pembrolizumab: $31,641M in FY2025, up 7.3% from a year earlier. That is the highest of the 10 years on record here.
Where the FY2025 figure comes from
“|| Keytruda | 7,906 | 7,904 | 15,810 | 7,205 | 7,956 | 15,161 | 8,142 | 8,337 | 31,641 | -1 | -2 | 4 | 2”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 31,641 | +7.3% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 29,482 | +17.9% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 25,011 | +19.5% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 20,937 | +21.8% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 17,186 | +19.5% | Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗ |
| FY2020 | Dec 31, 2020 | 14,380 | +29.7% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 11,084 | +54.6% | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2018 | Dec 31, 2018 | 7,171 | +88.3% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 3,809 | +171.7% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 1,402 | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Breakdown
What makes up keytruda (pembrolizumab
- Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — U.S. sales ($M)18,829 · FY2025
- Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — International sales ($M)12,812 · FY2025
- Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide reported growth YoY (%)7.0% · FY2025
- Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide constant-currency (ex-exchange) growth YoY (%)7.0% · FY2025
- Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched Q3 2025) — Worldwide sales ($M)40 · FY2025
Cite this data
StockData. (2026). Merck Keytruda (pembrolizumab ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-keytruda
See every metric in the Merck KPI table. Data updated Oct 26, 2026.